2016 American Transplant Congress

June 11-15, 2016 in Boston, MA

View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Evaluation of Patient-Reported Nonadherence with Tacrolimus Level Variability in Renal Transplant Recipients.

N. Parrish,¹ T. Kaiser,² A. McCann,¹ J. Aladimi,² J. Harris,³ A. Govil,² B. Abu Jawdeh,² G. Mogilishetty,² R. Alloway,² E. Woodle.²
Evaluation of Perioperative Anemia and Associated Transfusion Requirements in Adult Liver Transplant Recipients.

E. Aldag, P. Moghimi, R. Pedersen, A. Sahajpal, J. Clendenon, V. Gunabushanam, M. Irani, D. Kramer.
Evaluation of Polyomavirus (BK) Treatment and Clinical Outcomes in Pediatric Kidney Transplant Recipients: A >10 Year Single Center Retrospective Experience.

R. Liverman,¹ E. Kraus,¹ R. Garro,² B. Warshaw,² P. Winterberg,² R. George.²
Evaluation of Scoring Systems Predicting Patient Survival at Time of Kidney Transplantation.

O. Staeck, D. Khadzhynov, A. Kleinsteuber, L. Lehner, M. Duerr, K. Budde, F. Halleck.
Evaluation of T Cell Immunity in Elderly Solid Organ Transplant Recipients.

J. Schaenman,¹ Y. Korin,² T. Sidwell,² V. Groysberg,² E. Lum,¹ E. Huang,¹ S. Bunnapradist,¹ T. Pham,¹ G. Danovitch,¹ E. Reed.²
Evaluation of the Impact of the Implementation of a Specialty Pharmacy Program in the Treatment of Hepatitis C (HCV).

E. Aldag, T. Pedone, R. Pedersen, S. Besur, K. Safdar, A. Sahajpal.
Evaluation of the Long-Term Outcomes with Everolimus After Calcineurin Inhibitor Withdrawal: 36M Results of the H2304 and PROTECT Extension Studies.

L. Fischer,^1,2 J. Fung,¹ H. Metselaar,¹ G. Kaiser,^1,2 P. Schemmer,² P. Neuhaus,² G. Dong,³ P. Lopez,⁴ P. Bernhardt,⁴ H. Schlitt.²
Evaluation of the Major Adverse Cardiac Events Risk with Everolimus-Based Calcineurin Inhibitor Reduction or Withdrawal Regimen in Liver Transplant Recipients: 3-Year Post-Hoc Analysis of the Randomized H2304 Extension Study.

P. Bernhardt,¹ G. Dong,² P. Lopez,¹ G. Hustache,¹ G. Bader.¹
Evaluation of the Toxicity Profile of Proteasome Inhibitor-Based Therapy for Antibody Mediated Rejection.

A. Leino,¹ A. Lichvar,¹ B. Abu-Jawdeh,¹ A. Govil,¹ G. Mogilishetty,¹ M. Cardi,² J. Kremer,² M. Cuffy,¹ F. Paterno,¹ R. Alloway,¹ A. Shields,^1,2 E. Woodle.¹
Evaluation of the Utilization of Filgrastim in Kidney Transplant Recipients.

T. Poon,¹ C. Guerra.²

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z